[Inflammatory breast cancer].
The inflammatory breast cancer corresponds to 1-6% of breast tumors. It is an aggressive clinical entity being characterised by the incidence of local relapse and distant metastases superior to the other breast malign entities. Changes in its therapy have been observed: progressive innovating therapeutic strategies have been adopted, tendentiously multimodal ones, trying to alter the course of this pathology of such a unfavourable prognosis. Here we show a revision of the most significant facts in the evolution of the inflammatory breast carcinoma diagnosis and treatment, both as to the present development and future perspectives. Aspects of clinical diagnosis are emphasized as well as their corroboration with complementary diagnosis technics and their evolution before different approaching therapies.
Valsassina
Maria V
MV
Instituto Português de Oncologia de Francisco Gentil, Lisboa.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007249:Inflammation / Q000175:diagnosis / Q000628:therapy; D009362:Neoplasm Metastasis; D012008:Recurrence
D000970:Antineoplastic Agents